Table 1 Characteristics of the patients with ICI-induced diabetes
Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 74 | 60 | 67 | 64 | 66 | 88 | 62 | 61 | 54 | 40 |
Sex | M | F | M | M | M | F | M | M | M | M |
Underlying cancer | Lung CA | Ovarian CA | Melanoma | RCC | Melanoma | Melanoma | Lung CA | UC | HCC | Hard palate cancer |
Type of ICI | Nivolumab | Pembrolizumab | Ipilimumab + Nivolumab | Nivolumab | Nivolumab | Nivolumab | Pembrolizumab | Atezolizumab | Atezolizumab | Pembrolizumab |
Previous history of diabetes | - | - | - | - | Type 2 diabetes | - | - | - | - | - |
Time to diagnosis ICI-induced diabetes after starting ICI (Onset in month) | 19.6 | 3.8 | 10.7 | 9.0 | 1.5 | 5.0 | 19.8 | 18.1 | 8.9 | 21.3 |
Cycles of ICI at diagnosis ICI-induced diabetes | 42 | 2 | 20 | 18 | 3 | 9 | 20 | 24 | 3 | 6 |
DKA | + | - | + | + | - | + | + | - | + | - |
Glucose (mmol/L) | 70.9 | 29.6 | 27.5 | 70.8 | 57.3 | 55.2 | 20.2 | 38.8 | 50.5 | 56.9 |
HbA1C (mmol/mol) | 85 | 46 | 98 | 84 | 60 | 62 | 61 | 63 | 101 | 66 |
Random C-peptide (nmol/L) | 0.05 | < 0.03 | 0.06 | 0.04 | 0.13 | 0.08 | < 0.03 | < 0.03 | 0.09 | 0.06 |
Lipase (U/L) | 14 | NA | NA | 376 | 51 | 11 | 28 | NA | NA | NA |
Insulin Ab (%) | 4.6 | 6.1 | 7.1 | 7.1 | 5.5 | NA | 7.2 | NA | 4.6 | NA |
Anti-GAD* (U/mL, IU/mL) | 0.18 | 0.12 | < 0.11 | < 0.57 | < 0.57 | < 0.57 | < 0.57 | < 0.57 | < 0.57 | 624 |
Anti-IA2 (U/mL) | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 | < 0.95 |
Tumor response (By RECIST) | SD | PR | PD | SD | PD | PR | SD | SD | PD | SD |
Other irAE | Nil | Nil | Thyroiditis | Gastroenteritis | Nil | Nil | Colitis | Skin | Nil | Thyroiditis |
ICI therapy after DKA | Stop | Stop | Continue | Continue | Continue | Stop | Continue | Continue | Stop | Stop |